Can a diabetes drug protect failing kidneys?
NCT ID NCT05309785
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study looks at whether canagliflozin, a drug used for diabetes, can safely reduce protein in the urine (a sign of kidney damage) in people with advanced chronic kidney disease (CKD), including those on dialysis. About 35 adults with CKD stage 4 or 5 will take the drug for up to 26 weeks. The goal is to see if it helps protect the kidneys without causing serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CKD STAGE 4 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
McGill University Health Center
Montreal, Quebec, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a culturally smart program close the kidney transplant gap for hispanics?
- Steroids for kidney disease: do they prevent failure Long-Term?
- Could a simple supplement protect hearts in kidney failure?
- New device aims to keep dialysis fistulas working longer
- New tool helps kidney patients decide on organ offers
- Diabetes drug could help kidney dialysis patients